EDIT Earnings
Editas Medicine Inc
$
3.080
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Editas Medicine Inc(EDIT) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Editas Medicine Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| - | 2025-08-12 | After Hours | -0.41 | -0.63 | -53.66 | 850.00K | 3.58M | +320.94 | - | - |
| FY2025Q1 | 2025-05-12 | After Hours | -0.51 | -0.43 | +15.69 | 706.10K | 4.66M | +559.68 | -2.60 | -1.95 |
| FY2024Q4 | 2025-03-05 | Pre-Market | -0.39 | -0.55 | -41.03 | 37.17M | 30.60M | -17.67 | +16.48 | -16.48 |
| FY2024Q3 | 2024-11-04 | Pre-Market | -0.76 | -0.75 | +1.32 | 3.89M | 61.00K | -98.43 | -1.03 | +7.22 |
| FY2024Q2 | 2024-08-07 | Pre-Market | -0.69 | -0.82 | -18.84 | 4.14M | 513.00K | -87.62 | -12.18 | -14.74 |
| FY2024Q1 | 2024-05-08 | - | -0.63 | -0.76 | -20.63 | 7.30M | 1.14M | -84.44 | -11.36 | - |
| FY2023Q4 | 2024-02-28 | - | -0.52 | -0.23 | +55.77 | 14.31M | 60.05M | +319.61 | +24.94 | +3.16 |
| FY2023Q3 | 2023-11-03 | - | -0.64 | -0.55 | +14.06 | 3.42M | 5.34M | +56.08 | +18.21 | +11.95 |
| FY2023Q2 | 2023-08-02 | - | -0.76 | -0.56 | +26.32 | 4.39M | 2.89M | -34.23 | +5.66 | +2.89 |
| - | 2023-05-05 | - | -0.79 | -0.71 | +10.13 | - | - | - | +12.04 | +9.63 |
EDIT Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Editas Medicine Inc reported performance for , announced on 2025-08-12. The company achieved an EPS of -0.63, compared to analyst estimates of -0.41 by -53.66% . Revenue for the quarter reached 3.58M compared to expectations of 850.00K by 320.94% .
The stock price reacted with a 0.00% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Editas Medicine Inc growth trajectory and strategic initiatives.
EDIT Earnings Forecast
Looking ahead, Editas Medicine Inc(EDIT) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 1.80M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 48.99%, while EPS estimates have been Revise Downward by -5.92%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Upward by 64.61% . These revisions correlate with a 105.33% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Editas Medicine Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between EDIT's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+48.99%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-5.92%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward
+64.61%
In Past 3 Month
Stock Price
Go Up
+105.33%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:15.24M
--
EPS Estimate-Annual FY 2025:-1.84
—
Stock Price3.08
EDIT Revenue and EPS Performance: A Historical Perspective
Editas Medicine Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-08-12,After Hours):
EPS: -0.63 (Actual) vs.-0.41 (Estimate) (-53.66%)
Revenue: 3.58M (Actual) vs. 850.00K (Estimate) (320.94%)
Price Reaction: 0.00%(1-Day), %(5-Day)
FY2025Q1 (2025-05-12,After Hours):
EPS: -0.43 (Actual) vs.-0.51 (Estimate) (15.69%)
Revenue: 4.66M (Actual) vs. 706.10K (Estimate) (559.68%)
Price Reaction: -2.60%(1-Day), -1.95%(5-Day)
FY2024Q4 (2025-03-05,Pre-Market):
EPS: -0.55 (Actual) vs.-0.39 (Estimate) (-41.03%)
Revenue: 30.60M (Actual) vs. 37.17M (Estimate) (-17.67%)
Price Reaction: 16.48%(1-Day), -16.48%(5-Day)
Earnings Reaction
The chart below shows how EDIT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EDIT sees a +6.13% change in stock price 10 days leading up to the earnings, and a -0.05% change 10 days following the report. On the earnings day itself, the stock moves by +6.31%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed 34.50% on the day following the earnings release and then changed by 34.50% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
NUKK
Nukkleus Inc
4.430
USD
+3.26%
IMPP
Imperial Petroleum Inc
3.000
USD
-0.66%
ABOS
Acumen Pharmaceuticals Inc
1.270
USD
+0.79%
GSIT
GSI Technology Inc
3.200
USD
-2.74%
SUNS
Sunrise Realty Trust Inc
10.780
USD
+1.41%
KNDI
Kandi Technologies Group Inc
1.320
USD
+0.76%
FBRX
Forte Biosciences Inc
10.570
USD
-1.77%
AXTI
AXT Inc
2.180
USD
-2.24%
PROV
Provident Financial Holdings Inc
15.450
USD
+0.32%
CRDL
Cardiol Therapeutics Inc
1.110
USD
-1.77%
FAQ
What were the key highlights of EDIT’s latest earnings report for ?
EDIT reported its earnings on 2025-08-12, showcasing a revenue of 3.58M against an estimate of 850.00K, resulting in a 320.94% surprise. The EPS was -0.63, surpassing the expected -0.41 by -53.66% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did EDIT’s stock price react after the earnings release?
What are the revenue and EPS estimates for EDIT for 2025/Q2?
How does EDIT’s stock price correlate with earnings forecast revisions?
What should investors expect from EDIT’s next earnings report?